Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Investing

Lawmakers Seek To Overrule Cops’ Medical Decision and Follow the Advice of Addiction Doctors

by November 3, 2023
November 3, 2023
Lawmakers Seek To Overrule Cops’ Medical Decision and Follow the Advice of Addiction Doctors

Jeffrey A. Singer

Last March, I wrote about a recent episode of “Cops Practicing Medicine,” in which the Drug Enforcement Administration inserted itself into the medical management of opioid use disorder by proposing telehealth guidelines that undermined Congress’ intentions when it passed the Mainstreaming Addiction Treatment (MAT) Act at the end of 2022. The act removed the onerous rules and regulations surrounding the “X waiver” that the DEA required health care practitioners to obtain if they wanted to treat addiction with buprenorphine. The DEA’s proposed rule requires that any patients initially begun on buprenorphine via telehealth must see the prescribing practitioner in person within 30 days. The rule limits the prescription to a 30‐​day supply. The cops are concerned that patients will “abuse” or “divert” the buprenorphine into the black market if they do not get personally inspected by the physician after 30 days. The DEA has delayed implementing the proposed rule until the end of next year.

Doctors who treat substance use disorder begged to differ from the cops and offered a second medical opinion.

Addiction specialists are concerned that the proposed rule will reduce access to buprenorphine treatment and will undermine lawmakers’ intent to make it easier for people to get treatment for opioid use disorder. Dr. Brian Hurley, president‐​elect of the American Society of Addiction Medicine, told STAT News, “I don’t want federal rules dictating to me when I have to cut somebody off a medication that, on the basis of the information available to me, is still appropriate for the patient.”

It already averages 26 days to get a new appointment with a primary care provider, so there is no guarantee a new buprenorphine patient can get an appointment within the 30‐​day window. It might be even more difficult in rural or other areas with primary care provider shortages. The proposed DEA rule is likely to abruptly cease treatment for many patients who have just begun treatment using telehealth. Shortened or abrupt cessation of treatment will very likely cause patients to resume non‐​medical use of opioids in the dangerous black market.

Now, a bipartisan group of US senators has decided to go with the second opinion. Senators Sheldon Whitehouse (D‑RI), Lisa Murkowski (R‑AK), Marsha Blackburn (R‑TN), and Mark Warner (D‑VA) have introduced the Telehealth Response for E‑prescribing Addiction Therapy Services (TREATS) Act. The bill would allow providers to waive the in‐​person requirement. The senators argue that, in 2020, the DEA and the Substance Abuse and Mental Health Services Administration allowed patients to receive buprenorphine via telemedicine without requiring them to see clinicians in person as an emergency measure during the COVID-19 pandemic, and there is no evidence that patients abused or sold the medication on the black market.

Buprenorphine is a weak partial opioid agonist, unpopular among recreational drug users. Studies indicate that most people who buy buprenorphine on the street are self‐​administering medication‐​assisted treatment with buprenorphine because they can’t get appointments for treatment.

A shortcoming of the TREATS Act is that it doesn’t overrule the cops’ 30‐​day supply rule. Clinicians, not cops, should decide how much buprenorphine to prescribe based on their judgment and knowledge of their individual patient’s circumstances.

Senators Catherine Cortez Masto (D‑NV), Thom Tillis (R‑NC), Tim Kaine (D‑VA), Shelley Moore Capito (R‑WV), Amy Klobuchar (D‑MN), Mark Kelly (D‑AZ), and Cory Booker (D‑NJ have joined the bill as co‐​sponsors. Representatives David Trone (D‑MD), Jay Obernolte (R‑CA), and Brian Fitzpatrick (R‑PA) introduced the bill in the House.

It is refreshing to see lawmakers follow the medical advice of addiction medicine specialists over the advice of cops.

0
FacebookTwitterGoogle +Pinterest
previous post
Shopify Stock Shatters Expectations: What You Need to Know About Its Rise
next post
Hawley Wants to Restrict Funding of Political Speech

You may also like

There Are Many Ways to Fix Bank Regulation—Here’s...

December 16, 2024

Trump’s “Unimpeachable” Reputation

July 3, 2025

Idaho Bucks Managed Care Trend

December 5, 2023

The Divide Between America and Europe on Free...

March 12, 2025

Not Everything You Dislike Is a “Negative Externality”

January 24, 2025

The Place of Family and Religion in Civil...

April 4, 2025

Friday Feature: Oklahoma Parental Choice Tax Credit Program

June 9, 2023

Tariffs on Imports from China Are Still Too...

May 23, 2025

Pro-Brazilian Censors Strike Back: Digital Sovereignty Versus Free...

September 25, 2024

Will Big Sky Country Redefine Climate Policy?

April 15, 2024

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Trump repositions 2 nuclear submarines after ‘highly provocative’ Russian comments

      August 1, 2025
    • Trump endorses ‘MAGA warrior’ for RNC chairman after Whatley launches Senate campaign

      August 1, 2025
    • Friday Feature: Thales Academy

      August 1, 2025
    • Trump ends de minimis tariff exemption, hitting UK exporters and global e-commerce

      August 1, 2025
    • Aston Martin sells F1 team stake for $146m amid financial struggles

      August 1, 2025
    • China’s growing nuclear arsenal aims to break US alliances and dominate Asia, report warns

      August 1, 2025

    Categories

    • Business (8,651)
    • Investing (2,167)
    • Politics (16,277)
    • Stocks (3,228)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved